Question 1

What is Halia Therapeutics?

Accepted Answer

Halia Therapeutics is a Entity.

Question 2

How often does Halia Therapeutics appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 12 articles.

Question 3

When was Halia Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on May 12, 2026.

Question 4

When was Halia Therapeutics last mentioned in news?

Accepted Answer

Last active on Jun 29, 2026.

Question 5

What is Halia Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 65 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Halia Therapeutics in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Halia Therapeutics?

Accepted Answer

Halia Therapeutics' Ofirnoflast Phase 2 Results (May 12, 2026, 6 articles).

Question 8

How did the "Halia Therapeutics' Ofirnoflast Phase 2 Results" event impact Halia Therapeutics?

Accepted Answer

Halia Therapeutics announced positive final Phase 2 results for its drug ofirnoflast (HT-6184) in lower-risk myelodysplastic syndrome (LR-MDS) and appointed Win Myint as Chief Medical Officer, strengthening its clinical development capabilities.

Question 9

How did the "UAE Launches Alzheimer's Clinical Trial" event impact Halia Therapeutics?

Accepted Answer

Halia Therapeutics is a US-based biotechnology company that developed HT-4253, the investigational therapy being evaluated in the trial. The company has also established a new office in Abu Dhabi.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.